| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 49, Issue 3, 231-252, September 1997
Department of Pharmacology, Toxicology, and Therapeutics,
University of Kansas Medical Center, Kansas City, Kansas
I. Introduction
II. Molecular Biology
A. Receptor Taxonomy
B. Gene Organization and Receptor Synthesis
C. Receptor Isoforms
D. Protein Structure
III. Cellular Signaling Mechanisms
A. Signal Transduction in Expression Systems
B. Coupling in Brain
IV. Pharmacology
A. Radioligand Binding Studies
B. Functional Assays
V. Localization of D3 Receptors in Brain
A. Distribution of D3 Receptor Messenger Ribonucleic
Acid
1. Distribution in rat brain.
2. Distribution in human brain.
B. Distribution of Putative D3 Receptors
1. Distribution in rat brain.
2. Distribution in human brain.
C. Implications of Regional Distribution
VI. D3 Receptors in Cellular and Organismal Function
A. Role in Behavior
B. Role in Neuronal Activity
C. Role in Neurochemistry
D. Role in Development
VII. Regulation of D3 Receptor Density and Messenger
Ribonucleic Acid Expression
A. Modulation by Tonic Dopaminergic Activity
B. Modulation by Antidopaminergic Drugs
VIII. D3 Receptors and Disease
A. Genetic Linkage to Disease
B. Receptor Alterations in Neuropsychiatric Disorders
IX. Conclusion
References
This article has been cited by other articles:
|
|
 |
|
  D. H. Zald, R. L. Cowan, P. Riccardi, R. M. Baldwin, M. S. Ansari, R. Li, E. S. Shelby, C. E. Smith, M. McHugo, and R. M. Kessler Midbrain Dopamine Receptor Availability Is Inversely Associated with Novelty-Seeking Traits in Humans J. Neurosci., December 31, 2008; 28(53): 14372 - 14378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Witkin, B. Levant, A. Zapata, R. Kaminski, and M. Gasior The Dopamine D3/D2 Agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] Protects against Acute and Cocaine-Kindled Seizures in Mice: Further Evidence for the Involvement of D3 Receptors J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 930 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Collins, D. M. Calinski, A. H. Newman, P. Grundt, and J. H. Woods Food Restriction Alters N'-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (Pramipexole)-Induced Yawning, Hypothermia, and Locomotor Activity in Rats: Evidence for Sensitization of Dopamine D2 Receptor-Mediated Effects J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 691 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Martelle, R. Claytor, J. T. Ross, B. A. Reboussin, A. H. Newman, and M. A. Nader Effects of Two Novel D3-Selective Compounds, NGB 2904 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the Reinforcing and Discriminative Stimulus Effects of Cocaine in Rhesus Monkeys J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 573 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zeng, Y. Liu, Z. Wang, D. He, L. Huang, P. Yu, S. Zheng, J. E. Jones, L. D. Asico, U. Hopfer, et al. Activation of D3 Dopamine Receptor Decreases Angiotensin II Type 1 Receptor Expression in Rat Renal Proximal Tubule Cells Circ. Res., September 1, 2006; 99(5): 494 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chen, J. T. Kittler, S. J. Moss, and Z. Yan Dopamine D3 Receptors Regulate GABAA Receptor Function through a Phospho-Dependent Endocytosis Mechanism in Nucleus Accumbens J. Neurosci., March 1, 2006; 26(9): 2513 - 2521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Collins, J. M. Witkin, A. H. Newman, K. A. Svensson, P. Grundt, J. Cao, and J. H. Woods Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated Behavior J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 310 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hsu, D. M. Togasaki, E. Bezard, P. Sokoloff, J. W. Langston, D. A. Di Monte, and M. Quik Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 770 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Nally, A. Kinsella, O. Tighe, D. T. Croke, A. A. Fienberg, P. Greengard, and J. L. Waddington Ethologically Based Resolution of D2-Like Dopamine Receptor Agonist-versus Antagonist-Induced Behavioral Topography in Dopamine- and Adenosine 3',5'-Monophosphate-Regulated Phosphoprotein of 32 kDa "Knockout" Mutants Congenic on the C57BL/6 Genetic Background J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1281 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Millan, D. Cussac, A. Gobert, F. Lejeune, J.-M. Rivet, C. M. La Cour, A. Newman-Tancredi, and J.-L. Peglion S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 903 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Witkin, D. Dijkstra, B. Levant, H. C. Akunne, A. Zapata, S. Peters, H. E. Shannon, and M. Gasior Protection against Cocaine Toxicity in Mice by the Dopamine D3/D2 Agonist R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907] J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 957 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zeng, D. Wang, L. D. Asico, W. J. Welch, C. S. Wilcox, U. Hopfer, G. M. Eisner, R. A. Felder, and P. A. Jose Aberrant D1 and D3 Dopamine Receptor Transregulation in Hypertension Hypertension, March 1, 2004; 43(3): 654 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zeng, D. Wang, Z. Yang, Z. Wang, L. D. Asico, C. S. Wilcox, G. M. Eisner, W. J. Welch, R. A. Felder, and P. A. Jose Dopamine D1 Receptor Augmentation of D3 Receptor Action in Rat Aortic or Mesenteric Vascular Smooth Muscles Hypertension, March 1, 2004; 43(3): 673 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zeng, L. D. Asico, X. Wang, U. Hopfer, G. M. Eisner, R. A. Felder, and P. A. Jose Angiotensin II Regulation of AT1 and D3 Dopamine Receptors in Renal Proximal Tubule Cells of SHR Hypertension, March 1, 2003; 41(3): 724 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Narita, K. Mizuo, H. Mizoguchi, M. Sakata, M. Narita, L. F. Tseng, and T. Suzuki Molecular Evidence for the Functional Role of Dopamine D3 Receptor in the Morphine-Induced Rewarding Effect and Hyperlocomotion J. Neurosci., February 1, 2003; 23(3): 1006 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Vorel, C. R. Ashby Jr, M. Paul, X. Liu, R. Hayes, J. J. Hagan, D. N. Middlemiss, G. Stemp, and E. L. Gardner Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats J. Neurosci., November 1, 2002; 22(21): 9595 - 9603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Boehm and H. Kubista Fine Tuning of Sympathetic Transmitter Release via Ionotropic and Metabotropic Presynaptic Receptors Pharmacol. Rev., March 1, 2002; 54(1): 43 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Binder, B. Kinkead, M. J. Owens, and C. B. Nemeroff Neurotensin and Dopamine Interactions Pharmacol. Rev., December 1, 2001; 53(4): 453 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Price and Q. J. Pittman Dopamine D4 Receptor Activation Inhibits Presynaptically Glutamatergic Neurotransmission in the Rat Supraoptic Nucleus J Neurophysiol, September 1, 2001; 86(3): 1149 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. I. Tarazi, K. Zhang, and R. J. Baldessarini Long-Term Effects of Olanzapine, Risperidone, and Quetiapine on Dopamine Receptor Types in Regions of Rat Brain: Implications for Antipsychotic Drug Treatment J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 711 - 717. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. Cragg, C. Nicholson, J. Kume-Kick, L. Tao, and M. E. Rice Dopamine-Mediated Volume Transmission in Midbrain Is Regulated by Distinct Extracellular Geometry and Uptake J Neurophysiol, April 1, 2001; 85(4): 1761 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ilani, D. Ben-Shachar, R. D. Strous, M. Mazor, A. Sheinkman, M. Kotler, and S. Fuchs A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes PNAS, January 5, 2001; (2001) 21535398. [Abstract] [Full Text]
|
|
|
|
|
|
G. D. Stanwood, R. P. Artymyshyn, M.-P. Kung, H. F. Kung, I. Lucki, and P. McGonigle Quantitative Autoradiographic Mapping of Rat Brain Dopamine D3 Binding with [125I]7-OH-PIPAT: Evidence for the Presence of D3 Receptors on Dopaminergic and Nondopaminergic Cell Bodies and Terminals J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1223 - 1231. [Abstract] [Full Text]
|
|
|
|
|
|
G. D. Stanwood, I. Lucki, and P. McGonigle Differential Regulation of Dopamine D2 and D3 Receptors by Chronic Drug Treatments J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1232 - 1240. [Abstract] [Full Text]
|
|
|
|
|
|
J. Diaz, C. Pilon, B. Le Foll, C. Gros, A. Triller, J.-C. Schwartz, and P. Sokoloff Dopamine D3 Receptors Expressed by All Mesencephalic Dopamine Neurons J. Neurosci., December 1, 2000; 20(23): 8677 - 8684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Karpa, R. Lin, N. Kabbani, and R. Levenson The Dopamine D3 Receptor Interacts with Itself and the Truncated D3 Splice Variant D3nf: D3-D3nf Interaction Causes Mislocalization of D3 Receptors Mol. Pharmacol., October 1, 2000; 58(4): 677 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
E. Chu, T.-C. Chu, and D. E. Potter Mechanisms and Sites of Ocular Action of 7-Hydroxy-2-dipropylaminotetralin: A Dopamine3 Receptor Agonist J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 710 - 716. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.-M. Rivet, V. Audinot, T. Dubuffet, and G. Lavielle S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: I. Receptorial, Electrophysiological and Neurochemical Profile Compared with GR218,231 and L741,626 J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1048 - 1062. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.-M. Rivet, V. Audinot, A. Adhumeau, M. Brocco, J.-P. Nicolas, et al. S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at alpha 1- and alpha 2-Adrenergic Receptors: I. Receptorial, Neurochemical, and Electrophysiological Profile J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 38 - 53. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Millan, M. Brocco, J.-M. Rivet, V. Audinot, A. Newman-Tancredi, L. Maiofiss, S. Queriaux, N. Despaux, J.-L. Peglion, and A. Dekeyne S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at alpha 1- and alpha 2-Adrenergic Receptors: II. Functional Profile and a Multiparametric Comparison with Haloperidol, Clozapine, and 11 Other Antipsychotic Agents J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 54 - 66. [Abstract] [Full Text]
|
|
|
|
|
|
D. Cussac, A. Newman-Tancredi, V. Pasteau, and M. J. Millan Human Dopamine D3 Receptors Mediate Mitogen-Activated Protein Kinase Activation Via a Phosphatidylinositol 3-Kinase and an Atypical Protein Kinase C-Dependent Mechanism Mol. Pharmacol., November 1, 1999; 56(5): 1025 - 1030. [Abstract] [Full Text]
|
|
|
|
 |
|
 M.-Y. Jung and C. Schmauss Decreased c-fos Responses to Dopamine D1 Receptor Agonist Stimulation in Mice Deficient for D3 Receptors J. Biol. Chem., October 8, 1999; 274(41): 29406 - 29412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Piggott, E. F. Marshall, N. Thomas, S. Lloyd, J. A. Court, E. Jaros, D. Burn, M. Johnson, R. H. Perry, I. G. McKeith, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution Brain, August 1, 1999; 122(8): 1449 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. D. Ling, H. C. Robie, C. W. Tong, and P. M. Carvey Both the Antioxidant and D3 Agonist Actions of Pramipexole Mediate Its Neuroprotective Actions in Mesencephalic Cultures J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 202 - 210. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Millan, R. Schreiber, S. Monneyron, B. Denorme, C. Melon, S. Queriaux, and A. Dekeyne S-16924, a Novel, Potential Antipsychotic with Marked Serotonin1A Agonist Properties. IV. A Drug Discrimination Comparison with Clozapine J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 427 - 436. [Abstract] [Full Text]
|
|
|
|
|
|
M. Gasior, M. Shoaib, S. Yasar, M. Jaszyna, and S. R. Goldberg Acquisition of Nicotine Discrimination and Discriminative Stimulus Effects of Nicotine in Rats Chronically Exposed to Caffeine J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1053 - 1073. [Abstract] [Full Text]
|
|
|
|
|
|
A. Newman-Tancredi, D. Cussac, V. Audinot, V. Pasteau, S. Gavaudan, and M. J. Millan G Protein Activation by Human Dopamine D3 Receptors in High-Expressing Chinese Hamster Ovary Cells: A Guanosine-5'-O-(3-[35S]thio)-Triphosphate Binding and Antibody Study Mol. Pharmacol., March 1, 1999; 55(3): 564 - 574. [Abstract] [Full Text]
|
|
|
|
|
|
G. Di Giovanni, M. Di Mascio, V. Di Matteo, and E. Esposito Effects of Acute and Repeated Administration of Amisulpride, a Dopamine D2/D3 Receptor Antagonist, on the Electrical Activity of Midbrain Dopaminergic Neurons J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 51 - 57. [Abstract] [Full Text]
|
|
|
|
|
|
V. Audinot, A. Newman-Tancredi, A. Gobert, J.-M. Rivet, M. Brocco, F. Lejeune, L. Gluck, I. Desposte, K. Bervoets, A. Dekeyne, et al. A Comparative In Vitro and In Vivo Pharmacological Characterization of the Novel Dopamine D3 Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194 J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 187 - 197. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Millan, A. Gobert, A. Newman-Tancredi, V. Audinot, F. Lejeune, J.-M. Rivet, D. Cussac, J.-P. Nicolas, O. Muller, and G. Lavielle S 16924 ((R)-2-{1-[2-(2,3-Dihydro-Benzo[1,4] Dioxin-5-Yloxy)-Ethyl]-Pyrrolidin-3yl}-1-(4-Fluoro-Phenyl)-Ethanone), a Novel, Potential Antipsychotic with Marked Serotonin (5-HT)1A Agonist Properties: I. Receptorial and Neurochemical Profile in Comparison with Clozapine and Haloperidol J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1341 - 1355. [Abstract] [Full Text]
|
|
|
|
|
|
T. Ilani, D. Ben-Shachar, R. D. Strous, M. Mazor, A. Sheinkman, M. Kotler, and S. Fuchs A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes PNAS, January 16, 2001; 98(2): 625 - 628. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
